Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab

about

Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab

Item

http://www.wikidata.org/entity/Q27013710

description

2014 nî lūn-bûn

@nan

2014 թուականին հրատարակուած գիտական յօդուած

@hyw

2014 թվականին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Antigen-based immunotherapy fo ...... emerging role of blinatumomab

@ast

Antigen-based immunotherapy fo ...... emerging role of blinatumomab

@en

Antigen-based immunotherapy fo ...... emerging role of blinatumomab

@nl

type

Item

label

Antigen-based immunotherapy fo ...... emerging role of blinatumomab

@ast

Antigen-based immunotherapy fo ...... emerging role of blinatumomab

@en

Antigen-based immunotherapy fo ...... emerging role of blinatumomab

@nl

prefLabel

Antigen-based immunotherapy fo ...... emerging role of blinatumomab

@ast

Antigen-based immunotherapy fo ...... emerging role of blinatumomab

@en

Antigen-based immunotherapy fo ...... emerging role of blinatumomab

@nl

P1476

Antigen-based immunotherapy fo ...... emerging role of blinatumomab

@en

P2093

Mark Litzow

http://www.w3.org/2001/XMLSchema#string

P2860

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

CD19 as an attractive target for antibody-based therapy

An antibody-deficiency syndrome due to mutations in the CD19 gene

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.

A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission

ETV6 mutations in early immature human T cell leukemias

Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.

P304

79-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/ITT.S37292

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27471701

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

leukemia

P932

4918236

http://www.w3.org/2001/XMLSchema#string